This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.
May 2025 in “International Journal of Innovative Technologies in Social Science” This study found that regular caffeine consumption among medical students is linked to a higher risk of insomnia, with around 30% to nearly 50% of those surveyed reporting sleep disorders, and highlights the importance of health education on caffeine's side effects.
September 2025 in “Frontiers in Pharmacology” This study suggests that P. orientalis leaf-derived EVs could offer anxiolytic, antidepressant, and sleep-inducing benefits by affecting neurotransmitter levels and reducing inflammation, particularly when administered intranasally.
March 2022 in “Biomedical Journal of Scientific & Technical Research” This review discusses therapeutics for mitochondrial dysfunction and reports no new clinical findings.
156 citations
,
August 2014 in “Cochrane library” This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.